Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 05 August 2013 | By Louise Zornoza,
Brazil's National Agency for Sanitary Surveillance (Anvisa) has suspended processing of new applications for primary certification of bioavailability or bioequivalence for medical products by research centers located outside the country.
Applications filed prior to 31 July 2013, the date the suspension entered into force (RDC 37/13), will still be processed, regulators said.
The purpose of the suspension is to facilitate the review of existing rules governing foreign centers and the development of a new certification model that will be implemented later. The new certification model is being prepared now by the agency and will be released for public consultation after review and approval of the Board of Anvisa.
Read all Breaking News from RegLink
Tags: BA, BE, brazil, testing, certification